Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Average Target Price of $10.00

Emergent Biosolutions Inc. (NYSE:EBS) has earned a consensus recommendation of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

EBS has been the topic of a number of recent research reports. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They set an “underweight” rating on the stock. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 9th.

Insider Buying and Selling at Emergent Biosolutions

In related news, Director Donald Degolyer sold 17,800 shares of the business’s stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total value of $126,202.00. Following the completion of the sale, the director directly owned 111,921 shares in the company, valued at approximately $793,519.89. The trade was a 13.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On Emergent Biosolutions

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Emergent Biosolutions in the 2nd quarter valued at $39,525,000. Dimensional Fund Advisors LP lifted its position in shares of Emergent Biosolutions by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock valued at $22,884,000 after acquiring an additional 504,553 shares during the period. Ancora Advisors LLC bought a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at $8,949,000. Renaissance Technologies LLC lifted its position in shares of Emergent Biosolutions by 13.7% during the 1st quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock valued at $5,445,000 after acquiring an additional 78,900 shares during the period. Finally, Palisade Capital Management LP acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth $4,316,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Stock Performance

Shares of NYSE EBS opened at $7.03 on Monday. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The firm has a market cap of $360.17 million, a price-to-earnings ratio of -1.98 and a beta of 2.28. The stock’s fifty day moving average price is $6.08 and its two-hundred day moving average price is $7.45. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, equities analysts forecast that Emergent Biosolutions will post 0.13 EPS for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.